NDA 050780 · B Braun
Cefuroxime and Dextrose In Duplex Container
Cefuroxime Sodium · Injection
DiscontinuedLast checked: Nov 19, 2026Latest source record: Dec 5, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Feb 21, 2001
Approved uses
1
Original approval plus efficacy supplements
Registered trials
85
9 Phase 3, 14 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 5, 2020.
INDICATIONS AND USAGE Cefuroxime for Injection USP and Dextrose Injection USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes, and Escherichia coli . Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. Skin and Skin-Structure Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes, Escherichia coli, Klebsiella spp., and Enterobacter spp. Septicemia caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp. Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis, and Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains) in both males and females. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase producing strains). Clinical microbiological studies in skin and skin-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. Cefuroxime has been used successfully in these mixed infections in which several organisms...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER · CEFUROXIME SODIUM EQ 1.5GM BASE/VIAL · INJECTABLE, INJECTION · Discontinued · TE AP
- CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER · CEFUROXIME SODIUM EQ 750MG BASE/VIAL · INJECTABLE, INJECTION · Discontinued · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Cefuroxime" as an intervention, any sponsor and status, largest first.
- Study of Antibiotic Prophylaxis for Endophthalmitis Following Cataract SurgeryPivotal-lookingCompleted
City St George's, University of LondonAcademic, hospital or other
NCT00136344 · 35,000 participants · Start Sep 2003
Drug: Cefuroxime; Levofloxacin · For: Endophthalmitis
Sites: Salzburg, Austria; Antwerp, Belgium; Ghent, Belgium · 24 sites in all
- PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic BronchitisPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00132938 · 5,660 participants · Start Jan 2004 · Primary completion May 2006
Drug: telithromycin · For: Chronic Bronchitis
Sites: Bridgewater, New Jersey; Brussels, Belgium; Paris, France · 8 sites in all
- Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis.Pivotal-lookingCompleted
Zealand University HospitalAcademic, hospital or other
NCT04803422 · 3,193 participants · Start Apr 1, 2021 · Primary completion May 31, 2024
Drug: Antibiotic · For: Complicated Appendicitis
Sites: Slagelse, Denmark · 2 sites in all
- Does Additional Use of Preoperative Azithromycin Decrease Posthysterectomy InfectionsPivotal-lookingRecruiting
Helsinki University Central HospitalAcademic, hospital or other
NCT05337566 · 2,278 participants (planned) · Start Sep 5, 2022 · Primary completion Dec 31, 2027
Drug: Azithromycin Pill + Cefuroxime; Placebo + Cefuroxime · For: Infection Post Op; Hysterectomy; Antibiotics and 1 more
Sites: Helsinki, Finland; Jyväskylä, Finland; Kuopio, Finland · 6 sites in all
- Efficacy of Local Powder ProphylacticsPivotal-lookingStatus unknown
Ganga HospitalAcademic, hospital or other
NCT01372371 · 1,844 participants (planned) · Start Jun 2011 · Primary completion Jun 2012
Drug: Vancomycin; Vancomycin and Gentamycin and 1 more · For: Infection
Sites: Coimbatore, India
- Role of Delay and Antibiotics on Perforation Rate While Waiting AppendectomyPivotal-lookingCompleted
Helsinki University Central HospitalAcademic, hospital or other
NCT04378868 · 1,800 participants · Start May 18, 2020 · Primary completion Jan 23, 2023
Drug: Antibiotics, cefuroxime and metronidazole; No antibiotics · For: Appendicitis
Sites: Espoo, Finland; Helsinki, Finland
- The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) TrialPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT02800785 · 1,552 participants · Start May 2016 · Primary completion Mar 5, 2020
Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin · For: Appendicitis
Sites: Sylmar, California; Torrance, California; Aurora, Colorado · 25 sites in all
- Study of the Efficacy of Preoperative Cefuroxime Prophylaxis to Prevent Surgical Site Infection in Herniated Disk SurgeryPivotal-lookingCompleted
Centre Hospitalier Universitaire VaudoisAcademic, hospital or other
NCT00530400 · 1,369 participants · Start Apr 1994
Drug: cefuroxime; placebo · For: Surgical Wound Infection
Sites: Geneva, Switzerland; Lausanne, Switzerland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Addition of probenecid to oral β-lactam antibiotics: a systematic review and meta-analysis.
Wilson RC, Arkell P, Riezk A, et al. · J Antimicrob Chemother 2022 · Meta-Analysis, Systematic Review
- Antibiotic prevention of postcataract endophthalmitis: a systematic review and meta-analysis.
Kessel L, Flesner P, Andresen J, et al. · Acta Ophthalmol 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Relationship between pneumococcal serotypes and antimicrobial resistance: A systematic review and meta-analysis.
Ntim OK, Awere-Duodu A, Akwetey SA, et al. · J Glob Antimicrob Resist 2025 · Systematic Review, Meta-Analysis
- Perioperative Antibiotics to Prevent Acute Endophthalmitis after Ophthalmic Surgery: A Systematic Review and Meta-Analysis.
Huang J, Wang X, Chen X, et al. · PLoS One 2016 · Meta-Analysis, Systematic Review
- Comparison of Cefuroxime-Based Dual Therapy With Quadruple Therapy in Helicobacter pylori-Infected Treatment-Naive Patients: A Prospective, Multicenter, Randomized Controlled Trial.
Li JY, Song JC, Tian X, et al. · Helicobacter 2025 · Randomized Controlled Trial, Multicenter Study
- Risk factors for acute endophthalmitis following cataract surgery: a systematic review and meta-analysis.
Cao H, Zhang L, Li L, et al. · PLoS One 2013 · Meta-Analysis, Systematic Review
Sponsor: B Braun
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.